Poseida Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Poseida Therapeutics

09/03/2023 22:06

* Poseida Therapeutics Inc  PSTX.OQ  reported a quarterly
adjusted
loss of 39 cents​​ per share for the quarter ended in December.
The mean expectation of five analysts for the quarter was for a
loss of 22 cents per share.
    * Revenue fell 67.8% to $10.05 million from a year ago;
analysts
expected $61.69 million. 
    * Poseida Therapeutics Inc's reported EPS for the quarter
was a
loss of 39 cents​.
    * The mean earnings estimate of analysts had risen by
about 12.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Poseida Therapeutics Inc shares had risen by 2.6% this
quarter.
    * The company reported a quarterly loss of $33.32 million.
    * Wall Street's median 12-month price target for Poseida
Therapeutics Inc is $14.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 9 at 10:06 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.22          -0.39          Missed
 Sep. 30 2022      -0.65          0.92           Beat
 Jun. 30 2022      -0.76          -0.69          Beat
 Mar. 31 2022      -0.66          -0.93          Missed